Developer docs
API playgroundTry for free, no card

Search company profiles

TUM Technische Universität München

Full company profile

uuid004qiht

Namestring
TUM Technische Universität München
Legal namestring
Technische Universität München
Websiteurl
klinchem.med.tum.de
Company typeenum
Private
Founded yearint
1868
Descriptiontext

The Institut für Laboratoriumsmedizin (Institute for Laboratory Medicine) at TUM Technische Universität München is the centralized diagnostic laboratory serving the TUM Klinikum Rechts der Isar hospital in Munich. Founded as part of TUM in 1868 and operating under the legal framework of the Free State of Bavaria, the institute delivers a 24/7 clinical laboratory service spanning emergency and main laboratory work, blood depot management, hematology, hemostaseology, immunology and endocrinology, therapeutic drug monitoring, molecular genetic diagnostics, point-of-care testing coordination, and quality management. It serves treating physicians within the hospital by providing lab-medicine results that enable individualized therapy adjustment for inpatients.

Beyond clinical diagnostics, the institute operates five principal investigator-led research laboratories (Buchner, Frede, Jellusova, Ruland, and Winter) focused on immune system regulation and dysfunction in disease processes, with cross-disciplinary collaboration into TUM's technical and natural science departments to develop novel diagnostic and therapeutic approaches for benign and malignant diseases. Three central core facility services — the Liquid Biobank, Labordiagnostik für Klinische Studien, and the Core Facility Zellanalytik — extend the institute's offering into translational and clinical-trial support. Director Prof. Jürgen Ruland leads the institute, and a scheduled name change is set for June 2026.

The entity is a non-profit public institution funded primarily by the Free State of Bavaria, with service revenue flowing through the German statutory health insurance system via the parent hospital. Pricing is not publicly disclosed. There are no funding rounds, no external investors, no M&A activity, no patents, and no commercial go-to-market motion; the institute's distribution channel is exclusively the internal hospital system. Strategic positioning in 2024 included association with the FOR 5560 research consortium and the award of the Jürgen Manchot Research Professorship to the director.

Short descriptiontext

The Institut für Laboratoriumsmedizin at TUM is a public university institute that provides 24/7 clinical laboratory diagnostic services for the TUM Klinikum Rechts der Isar hospital and conducts immunology-focused translational research across five principal investigator-led laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Markets served

Serves global market

Keyword5 values
clinical laboratory diagnostics, medical laboratory services, hematology diagnostics, molecular genetic testing, clinical trial diagnostics
Industry4 codes
1Clinical Chemistry & Immunoassay Laboratories
CodeHLAFAMABPrimaryYes
2Central Laboratory Services (Core Lab Operations)
CodeHLAGAEAAPrimaryNo
3Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
CodeHLAGAEABPrimaryNo
4Hematology & Coagulation Laboratories
CodeHLAFAMACPrimaryNo
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Laboratory Diagnostics
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The Institut für Laboratoriumsmedizin at TUM operates the central diagnostic laboratories of TUM Klinikum Rechts der Isar on a round-the-clock basis, delivering clinical laboratory diagnostic results to treating physicians across specialties including hematology, hemostaseology, immunology, endocrinology, therapeutic drug monitoring, molecular genetic diagnostics, and point-of-care testing. The institute also conducts immunology-focused research into immune system regulation and dysfunction in disease, and operates supporting core facilities (Liquid Biobank, Clinical Study Diagnostics, Cell Analytics) that enable translational research and clinical trial support.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The Institut für Laboratoriumsmedizin at TUM provides a comprehensive portfolio of clinical laboratory diagnostic services organized across multiple specialized laboratory areas (Notfall- und Hauptlabor, Blutdepot, Hämatologie, Hämostaseologie, Immunologie und Endokrinologie, Therapeutisches Drug-Monitoring, Molekulargenetische Diagnostik, POCT-Koordination, and Qualitätsmanagement), operating around the clock to support patient care at the TUM Klinikum Rechts der Isar. The institute also maintains extensive research laboratories (Labor Buchner, Frede, Jellusova, Ruland, and Winter) focused on immune system regulation and disease mechanisms, supported by core facilities including Liquid Biobank, Labordiagnostik für Klinische Studien, and Core Facility Zellanalytik.

Product and service2 records
1Notfall- und Hauptlabor (Emergency and Main Laboratory)
CategoryClinical Diagnostic Service
2Blutdepot (Blood Depot)
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TUM Technische Universität München

Clinical Laboratory Diagnosticsklinchem.med.tum.de

The Institut für Laboratoriumsmedizin at TUM is a public university institute that provides 24/7 clinical laboratory diagnostic services for the TUM Klinikum Rechts der Isar hospital and conducts immunology-focused translational research across five principal investigator-led laboratories.

What TUM Technische Universität München does

The Institut für Laboratoriumsmedizin (Institute for Laboratory Medicine) at TUM Technische Universität München is the centralized diagnostic laboratory serving the TUM Klinikum Rechts der Isar hospital in Munich. Founded as part of TUM in 1868 and operating under the legal framework of the Free State of Bavaria, the institute delivers a 24/7 clinical laboratory service spanning emergency and main laboratory work, blood depot management, hematology, hemostaseology, immunology and endocrinology, therapeutic drug monitoring, molecular genetic diagnostics, point-of-care testing coordination, and quality management. It serves treating physicians within the hospital by providing lab-medicine results that enable individualized therapy adjustment for inpatients.

Beyond clinical diagnostics, the institute operates five principal investigator-led research laboratories (Buchner, Frede, Jellusova, Ruland, and Winter) focused on immune system regulation and dysfunction in disease processes, with cross-disciplinary collaboration into TUM's technical and natural science departments to develop novel diagnostic and therapeutic approaches for benign and malignant diseases. Three central core facility services — the Liquid Biobank, Labordiagnostik für Klinische Studien, and the Core Facility Zellanalytik — extend the institute's offering into translational and clinical-trial support. Director Prof. Jürgen Ruland leads the institute, and a scheduled name change is set for June 2026.

The entity is a non-profit public institution funded primarily by the Free State of Bavaria, with service revenue flowing through the German statutory health insurance system via the parent hospital. Pricing is not publicly disclosed. There are no funding rounds, no external investors, no M&A activity, no patents, and no commercial go-to-market motion; the institute's distribution channel is exclusively the internal hospital system. Strategic positioning in 2024 included association with the FOR 5560 research consortium and the award of the Jürgen Manchot Research Professorship to the director.

TUM Technische Universität München firmographics

Firmographics
Name
TUM Technische Universität München
Legal name
Technische Universität München
Website
https://klinchem.med.tum.de
Company type
Private
Founded year
1868
Operating status
Operating
Headcount range
1–10 employees
Short description
The Institut für Laboratoriumsmedizin at TUM is a public university institute that provides 24/7 clinical laboratory diagnostic services for the TUM Klinikum Rechts der Isar hospital and conducts immunology-focused translational research across five principal investigator-led laboratories.
Ownership category
akta.pro rank

TUM Technische Universität München industry classification

Industry
Product category
Clinical Laboratory Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro primary industry
Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)
akta.pro secondary industries
Central Laboratory Services (Core Lab Operations) (HLAGAEAA), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Hematology & Coagulation Laboratories (HLAFAMAC)

Keywords

  • Clinical laboratory diagnostics
  • Medical laboratory services
  • Hematology diagnostics
  • Molecular genetic testing
  • Clinical trial diagnostics

TUM Technische Universität München business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Distribution channels1 record

Marketing channels1 record

TUM Technische Universität München product offering

Product offering

Core offering

The Institut für Laboratoriumsmedizin at TUM operates the central diagnostic laboratories of TUM Klinikum Rechts der Isar on a round-the-clock basis, delivering clinical laboratory diagnostic results to treating physicians across specialties including hematology, hemostaseology, immunology, endocrinology, therapeutic drug monitoring, molecular genetic diagnostics, and point-of-care testing. The institute also conducts immunology-focused research into immune system regulation and dysfunction in disease, and operates supporting core facilities (Liquid Biobank, Clinical Study Diagnostics, Cell Analytics) that enable translational research and clinical trial support.

Product overview

The Institut für Laboratoriumsmedizin at TUM provides a comprehensive portfolio of clinical laboratory diagnostic services organized across multiple specialized laboratory areas (Notfall- und Hauptlabor, Blutdepot, Hämatologie, Hämostaseologie, Immunologie und Endokrinologie, Therapeutisches Drug-Monitoring, Molekulargenetische Diagnostik, POCT-Koordination, and Qualitätsmanagement), operating around the clock to support patient care at the TUM Klinikum Rechts der Isar. The institute also maintains extensive research laboratories (Labor Buchner, Frede, Jellusova, Ruland, and Winter) focused on immune system regulation and disease mechanisms, supported by core facilities including Liquid Biobank, Labordiagnostik für Klinische Studien, and Core Facility Zellanalytik.

Differentiator

Problem solved

Functional benefit

Products and services

  • Notfall- und Hauptlabor (Emergency and Main Laboratory)
  • Blutdepot (Blood Depot)

Companies that use TUM Technische Universität München

Customer profile

Segments1 record

Ideal customer profiles2 records

TUM Technische Universität München technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TUM Technische Universität München partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights4 records

TUM Technische Universität München competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

TUM Technische Universität München social profiles

Digital presence

TUM Technische Universität München financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TUM Technische Universität München leadership team

Management profile

Number of profiles

Profiles1 record

TUM Technische Universität München funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TUM Technische Universität München M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TUM Technische Universität München

What does TUM Technische Universität München do?

The Institut für Laboratoriumsmedizin at TUM operates the central diagnostic laboratories of TUM Klinikum Rechts der Isar on a round-the-clock basis, delivering clinical laboratory diagnostic results to treating physicians across specialties including hematology, hemostaseology, immunology, endocrinology, therapeutic drug monitoring, molecular genetic diagnostics, and point-of-care testing. The institute also conducts immunology-focused research into immune system regulation and dysfunction in disease, and operates supporting core facilities (Liquid Biobank, Clinical Study Diagnostics, Cell Analytics) that enable translational research and clinical trial support.

Is TUM Technische Universität München a public or private company?

TUM Technische Universität München is a private company. It is classified as state government owned and is currently operating.

When was TUM Technische Universität München founded?

TUM Technische Universität München was founded in 1868. It employs 1 to 10 people.

Does TUM Technische Universität München have an API?

No public API is recorded for TUM Technische Universität München.

What industry is TUM Technische Universität München in?

TUM Technische Universität München's product category is Clinical Laboratory Diagnostics. Its primary akta.pro industry code is HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories, with a secondary code of HLAGAEAA, Central Laboratory Services (Core Lab Operations). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsSatellite Images Show Tides Vary by Metre in One BayResearchers at the University of Oxford and Technische Universität München published a study in Nature Communications: Earth and Environment describing a method that estimates tides at 100-metre intervals using Landsat shoreline images. The technique infers sea level from the moving waterline on sloping beaches, revealing tidal height differences of nearly one metre across New Zealand's South Taranaki Bight. The authors say the approach could improve coastal flood modelling and tide forecasts.Quantum ZeitgeistNoisy Bosonic Broadcast Channels Enable AchievableResearchers Zuhra Amiri and Janis Nötzel from Technische Universität München have established achievable identification rates for noisy bosonic broadcast channels, enabling reliable message verification without full decoding. The study utilizes quantum hypothesis testing and discrete approximations to derive capacity bounds in infinite-dimensional Hilbert spaces, addressing challenges posed by additive thermal noise. This work provides a mathematical framework for secure and efficient quantum communication protocols with implications for future quantum networks.EssopenarchiveReal Time Event Detection in Smart City Surveillance Latency Optimization Through Neural System Design AuthorsResearchers from the Technische Universität München and Freie Universität Berlin developed a latency-optimized neural pipeline for real-time smart city surveillance systems. The study demonstrated that this framework achieved a 41.6% latency reduction and maintained over 91% prediction accuracy by integrating asynchronous input queues and early-exit neural layers.EssopenarchiveReal Time Event Detection in Smart City Surveillance Latency Optimization Through Neural System Design AuthorsResearchers from Technische Universität München and Freie Universität Berlin developed a latency-optimized neural pipeline for real-time smart city surveillance. The system achieved a 41.6% latency reduction and processed 97.6% of security events within one second on consumer-grade GPUs. This framework offers a scalable pathway for next-generation urban monitoring infrastructures by balancing high throughput with maintained prediction accuracy.European UnionSoft-exoskeleton suit To Restore Autonomous LocomotionThe STROLL project, funded by the European Research Council and hosted by Technische Universitaet Muenchen, aims to develop a soft, wearable robotic exoskeleton resembling a pair of pants to restore walking in patients with lower-body paralysis from stroke or spinal cord injury. The project combines textile-based actuators, lower-body tactile sensors and advanced locomotion control, with a net EU contribution of €2,449,676.Cosmetics & ToiletriesMeasuring Tack in Hair Styling ProductsScientists from Technische Universität München have developed a new technique using nylon fiber assemblies and cylindrical stamps to measure the tack properties of hair styling polymers. This method aims to assist formulators in creating products with a natural feel, which is preferred by consumers. The research was published in the American Chemical Society's Applied Polymer Materials.PR NewswireTechnische Universität München Hospital is First in Germany to Treat Cancer Patients with Accuray Radixact® SystemAccuray Incorporated announced that Klinikum rechts der Isar der Technische Universität München has become the first hospital in Germany to treat cancer patients with the company's Radixact System, a next-generation helical radiation therapy platform. The hospital treated patients for breast cancer, head and neck tumors, prostate cancer, and spinal tumors after upgrading from an earlier TomoTherapy System. The Radixact System offers a higher dose rate of 1000 MU/minute and imaging time that is 66 percent faster than the previous platform, enabling shorter treatment times and improved patient experience.SnmjournalsPreclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate CancerResearchers from the Technische Universität München developed and evaluated 99mTc-PSMA-I&S, a cost-effective radiotracer for SPECT imaging and radioguided surgery in prostate cancer. The study established a robust kit-labeling procedure and demonstrated through preclinical models and first-in-human trials that the tracer effectively identifies metastatic lymph nodes during surgery. Initial patient data indicate the tracer's comparable or superior performance to existing alternatives like 111In-PSMA-I&T.IMAADivide And Conquer: How Successful M&A Deals Split The SynergiesA BCG and Technische Universität München study finds that about two-thirds of public M&A deals destroy acquirer value, but successful ones create value by sharing synergies, with sellers capturing on average 31 percent of expected synergies. The authors note cost synergies dominate disclosures, with 94 percent of announcements mentioning only cost synergies versus 5 percent mentioning revenue synergies.